Loading patent…
AssigneesQx Therapeutics Inc., Yale University
InventorsDianqing Wu, Ho Yin Lo
Estimating the term…
The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.
A method for treating or reducing the severity of a lung injury associated with a coronavirus infection comprising administering to a human subject in need thereof a therapeutically effective amount of nintedanib, or a pharmaceutically acceptable salt or solvate thereof.
A method for treating or reducing the severity of a lung injury associated with a coronavirus infection comprising administering to a human subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:
A pharmaceutical composition for treating or reducing the severity of a lung injury associated with a SARS-CoV-2 infection, comprising:
Dependencies are inferred from the claim text.